F M Investments LLC Invests $1.27 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO)

F M Investments LLC purchased a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 45,778 shares of the company's stock, valued at approximately $1,274,000. F M Investments LLC owned 0.07% of Akero Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of AKRO. AlphaQuest LLC boosted its position in Akero Therapeutics by 32,588.0% during the fourth quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock valued at $227,000 after acquiring an additional 8,147 shares during the last quarter. Sei Investments Co. bought a new stake in Akero Therapeutics in the fourth quarter valued at $303,000. KLP Kapitalforvaltning AS bought a new stake in Akero Therapeutics in the 4th quarter valued at about $306,000. XTX Topco Ltd acquired a new position in shares of Akero Therapeutics during the third quarter worth approximately $308,000. Finally, Proficio Capital Partners LLC acquired a new position in Akero Therapeutics during the 4th quarter valued at about $320,000.

Insider Transactions at Akero Therapeutics

In other news, Director G. Walmsley Graham bought 200,000 shares of the stock in a transaction dated Thursday, January 30th. The stock was purchased at an average cost of $48.00 per share, for a total transaction of $9,600,000.00. Following the transaction, the director now owns 1,000,000 shares of the company's stock, valued at $48,000,000. The trade was a 25.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Timothy Rolph sold 31,250 shares of the company's stock in a transaction on Monday, January 27th. The shares were sold at an average price of $55.77, for a total transaction of $1,742,812.50. Following the sale, the insider now directly owns 170,237 shares in the company, valued at approximately $9,494,117.49. The trade was a 15.51 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders purchased 341,309 shares of company stock worth $15,863,578 and sold 287,458 shares worth $13,689,886. 7.94% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on AKRO. UBS Group increased their price target on Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a research report on Friday, January 31st. Bank of America upgraded shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and boosted their target price for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. Morgan Stanley restated an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. HC Wainwright upped their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Finally, Canaccord Genuity Group raised their target price on Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $76.29.

Akero Therapeutics Stock Down 0.8 %

AKRO stock traded down $0.29 during midday trading on Thursday, hitting $37.15. The stock had a trading volume of 162,508 shares, compared to its average volume of 853,202. The business has a 50-day moving average of $43.79 and a two-hundred day moving average of $36.00. The firm has a market cap of $2.96 billion, a price-to-earnings ratio of -9.92 and a beta of -0.18. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics, Inc. has a 52-week low of $17.86 and a 52-week high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). As a group, equities research analysts forecast that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.